A new immunotherapy, tested for the blood cancer acute lymphoblastic leukemia (ALL), demonstrated impressive results in early clinical trials, of among several dozen patients.
Read more at Drug Discovery & Development.
Related Articles Read More >
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
